Shares of Hims & Hers Health (HIMS) plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in Eli Lilly’s (LLY) Wegovy and Novo Nordisk’s (NVO) Ozempic has been ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.

Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is over. Key Points ...

Current weight-loss methods such as lifestyle changes, surgery, and popular therapies like Novo Nordisk's Wegovy and Eli ...

Weight loss drugs continue to make headlines.  A new study conducted by researchers from the University of Southern ...

There are new rules for people buying weight loss injections online. Weight loss injections such as Wegovy or Mounjaro work by reducing food cravings. The new guidance will help prevent vulnerable ...